Table 1.
Baseline characteristics of participants in the Boston Kidney Biopsy Cohort
| Baseline Characteristics | Boston Kidney Biopsy Cohort Participants, n=549 |
|---|---|
| Clinical characteristics | |
| Age, yr | 52±17 |
| Women | 288 (52) |
| Race | |
| Black | 105 (19) |
| White | 347 (63) |
| Other | 97 (18) |
| eGFR, ml/min per 1.73 m2 | 58±36 |
| eGFR categories | |
| Category 1 (eGFR>90 ml/min per 1.73 m2) | 132 (24) |
| Category 2 (eGFR=60–89 ml/min per 1.73 m2) | 92 (17) |
| Category 3A (eGFR=45–59 ml/min per 1.73 m2) | 81 (15) |
| Category 3B (eGFR=30–44 ml/min per 1.73 m2) | 91 (17) |
| Category 4 (eGFR=15–29 ml/min per 1.73 m2) | 101 (18) |
| Category 5 (eGFR<15 ml/min per 1.73 m2) | 52 (9) |
| Proteinuria, g/g creatinine | 1.7 [0.4–3.8] |
| Proteinuria categories, g/g creatinine | |
| Category 1, <0.15 | 73 (13) |
| Category 2, 0.16–1 | 139 (25) |
| Category 3, 1.1–3.5 | 175 (32) |
| Category 4, >3.5 | 162 (30) |
| Reason for biopsy | |
| Proteinuria | 312 (57) |
| Hematuria | 134 (24) |
| Nephrotic syndrome | 69 (13) |
| Nephritic syndrome | 14 (3) |
| Abnormal eGFR/other | 336 (61) |
| Primary clinicopathologic diagnosis | |
| Proliferative glomerulonephritis | 162 (30) |
| Nonproliferative glomerulopathy | 96 (17) |
| Diabetic nephropathy | 64 (12) |
| Advanced glomerulosclerosis | 62 (11) |
| Vascular disease | 52 (9) |
| Tubulointerstitial disease | 47 (9) |
| Paraprotein-related disease | 35 (6) |
| Other | 31 (6) |
| Comorbid conditions | |
| Diabetes mellitus | 122 (22) |
| Hypertension | 287 (52) |
| SLE | 90 (16) |
| Hepatitis C | 11 (2) |
| Hepatitis B | 4 (1) |
| HIV | 6 (1) |
| Malignancy | 80 (15) |
| Medications | |
| ACEi/ARB | 257 (47) |
| MRA | 14 (3) |
| Calcium channel blockers | 137 (25) |
| β-blockers | 166 (30) |
| Immunosuppression | 102 (19) |
| Corticosteroids | 123 (22) |
Data are presented as mean±SD, median [interquartile range], or count with frequency (percentage) for binary and categorical variables. Data on proteinuria were missing for seven individuals. Percentages do not add to 100 as there may have been more than one reason for a kidney biopsy. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor blocker.